The phase 3 pivotal ADMIRAL trial randomized (2:1) 371 patients with relapsed FLT3-mutated AML to gilteritinib 120 mg daily (n = 247) or investigator choice salvage chemotherapy (both high- and low-dose chemotherapy) (n = 124)164. The gene discussed is FLT3; the disease is acute myeloid leukemia.